半合成糖肽类抗生素LY191145对耐万古霉素肠球菌及其他革兰氏阳性菌的抗菌活性。
Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.
作者信息
Nicas T I, Mullen D L, Flokowitsch J E, Preston D A, Snyder N J, Stratford R E, Cooper R D
机构信息
Lilly Research Laboratories, Indianapolis, Indiana 46285, USA.
出版信息
Antimicrob Agents Chemother. 1995 Nov;39(11):2585-7. doi: 10.1128/AAC.39.11.2585.
Abstract
LY191145 is the prototype of a series of compounds with activities against vancomycin-resistant enterococci derived by modification of the glycopeptide antibiotic LY264826. LY191145 had MICs for vancomycin- and teicoplanin-resistant enterococci of < or = 4 micrograms/ml for 50% of isolates and < or = 16 micrograms/ml for 90% of isolates. Its MICs for vancomycin-resistant, teicoplanin-susceptible enterococci were 1 to 8 micrograms/ml. LY191145 retains the potent activities of its parent compound against staphylococci and streptococci. In vivo studies in a mouse infection model confirmed these activities. This compound indicates the potential of semisynthetic glycopeptides as agents against antibiotic-resistant gram-positive bacteria.
摘要
LY191145是一系列通过修饰糖肽抗生素LY264826而获得的对耐万古霉素肠球菌具有活性的化合物的原型。LY191145对50%的耐万古霉素和替考拉宁肠球菌分离株的最低抑菌浓度（MIC）≤4微克/毫升，对90%的分离株MIC≤16微克/毫升。其对耐万古霉素、对替考拉宁敏感的肠球菌的MIC为1至8微克/毫升。LY191145保留了其母体化合物对葡萄球菌和链球菌的强效活性。在小鼠感染模型中的体内研究证实了这些活性。该化合物表明半合成糖肽作为抗耐药革兰氏阳性菌药物的潜力。
相似文献
1
Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.
Antimicrob Agents Chemother. 1995 Nov;39(11):2585-7. doi: 10.1128/AAC.39.11.2585.
2
Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.
Antimicrob Agents Chemother. 1996 Sep;40(9):2194-9. doi: 10.1128/AAC.40.9.2194.
3
European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
Diagn Microbiol Infect Dis. 1998 Aug;31(4):563-71. doi: 10.1016/s0732-8893(98)00053-4.
4
In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
Antimicrob Agents Chemother. 1997 Oct;41(10):2165-72. doi: 10.1128/AAC.41.10.2165.
5
Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
J Antimicrob Chemother. 1997 Sep;40(3):423-5. doi: 10.1093/jac/40.3.423.
6
Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
Drugs. 1997;54 Suppl 6:11-20. doi: 10.2165/00003495-199700546-00005.
7
The in-vitro activity of LY333328, a new glycopeptide, against clinical isolates of vancomycin-resistant enterococci.
Adv Exp Med Biol. 1997;418:483-5. doi: 10.1007/978-1-4899-1825-3_115.
8
Glycopeptide tolerance in bacteria causing endocarditis.
J Antimicrob Chemother. 1999 Jul;44(1):121-4. doi: 10.1093/jac/44.1.121.
9
Comparative in vitro activities of AC98-6446, a novel semisynthetic glycopeptide derivative of the natural product mannopeptimycin alpha, and other antimicrobial agents against gram-positive clinical isolates.
Antimicrob Agents Chemother. 2004 Mar;48(3):739-46. doi: 10.1128/AAC.48.3.739-746.2004.
10
[Glycopeptide resistant enterococci. Occurrence, distribution, resistance transmission, significance].
Wien Klin Wochenschr. 1997 May 9;109(9):293-300.
引用本文的文献
1
Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
Antimicrob Agents Chemother. 2009 Aug;53(8):3375-83. doi: 10.1128/AAC.01710-08. Epub 2009 May 26.
2
Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2005 Mar;49(3):1127-34. doi: 10.1128/AAC.49.3.1127-1134.2005.
3
Intravenous mouse infection model for studying the pathology of Enterococcus faecalis infections.
Infect Immun. 2003 Mar;71(3):1434-41. doi: 10.1128/IAI.71.3.1434-1441.2003.
4
Hexapeptide derivatives of glycopeptide antibiotics: tools for mechanism of action studies.
Antimicrob Agents Chemother. 2002 Aug;46(8):2344-8. doi: 10.1128/AAC.46.8.2344-2348.2002.
5
Antibiotic resistance: a current perspective.
Br J Clin Pharmacol. 1999 Aug;48(2):109-24. doi: 10.1046/j.1365-2125.1999.00997.x.
6
Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model.
Antimicrob Agents Chemother. 1999 Mar;43(3):592-7. doi: 10.1128/AAC.43.3.592.
7
Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.
Antimicrob Agents Chemother. 1998 Oct;42(10):2564-8. doi: 10.1128/AAC.42.10.2564.
8
Fecal carriage of vancomycin-resistant enterococci in hospitalized patients and those living in the community in The Netherlands.
J Clin Microbiol. 1997 Dec;35(12):3026-31. doi: 10.1128/jcm.35.12.3026-3031.1997.
9
The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics.
Antimicrob Agents Chemother. 1997 Mar;41(3):497-503. doi: 10.1128/AAC.41.3.497.
10
Molecular interactions of a semisynthetic glycopeptide antibiotic with D-alanyl-D-alanine and D-alanyl-D-lactate residues.
Antimicrob Agents Chemother. 1997 Jan;41(1):66-71. doi: 10.1128/AAC.41.1.66.
本文引用的文献
1
Structure-activity relationships of vancomycin-type glycopeptide antibiotics.
J Antibiot (Tokyo). 1993 Aug;46(8):1181-95. doi: 10.7164/antibiotics.46.1181.
2
Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin.
Clin Infect Dis. 1993 Jun;16(6):750-5. doi: 10.1093/clind/16.6.750.
3
Synthesis and antibacterial activity of N-acyl vancomycins.
J Antibiot (Tokyo). 1988 Oct;41(10):1430-8. doi: 10.7164/antibiotics.41.1430.
4
Pharmacokinetics of [14C]teicoplanin in male rats after single intravenous dose.
Antimicrob Agents Chemother. 1986 Nov;30(5):733-8. doi: 10.1128/AAC.30.5.733.
5
Synthesis and antibacterial evaluation of N-alkyl vancomycins.
J Antibiot (Tokyo). 1989 Jan;42(1):63-72. doi: 10.7164/antibiotics.42.63.
6
Vancomycin-resistant enterococci.
Lancet. 1988;1(8575-6):57-8. doi: 10.1016/s0140-6736(88)91037-9.
7
Activity of glycopeptides against vancomycin-resistant gram-positive bacteria.
Antimicrob Agents Chemother. 1989 Sep;33(9):1477-81. doi: 10.1128/AAC.33.9.1477.
8
The structural relationships of A82846B and its hydrolysis products with chloroorienticins A, B and C.
J Antibiot (Tokyo). 1989 Sep;42(9):1438-40. doi: 10.7164/antibiotics.42.1438.
9
Inducible resistance to vancomycin in Enterococcus faecium D366.
J Infect Dis. 1989 Jun;159(6):1095-104. doi: 10.1093/infdis/159.6.1095.
10
Transferable vancomycin and teicoplanin resistance in Enterococcus faecium.
Antimicrob Agents Chemother. 1989 Jan;33(1):10-5. doi: 10.1128/AAC.33.1.10.
Zotero 插件